Collegium Pharma (COLL) Misses Q1 EPS by 8c

Collegium Pharma (NASDAQ: COLL) reported Q1 EPS of ($0.57), $0.08 worse than the analyst estimate of ($0.49). Revenue for the quarter came in at $63.7 million versus the consensus estimate of $59.75 million.

For earnings history and earnings-related data on Collegium Pharma (COLL) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Creatd files Form S-1 and reports Q1 2026 financial results
• AeroVironment restates quarterly financials, citing $89M goodwill error